title: Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice.
abstract: The atypical antipsychotic clozapine has been reported to be associated with metabolic adverse effects, including type-2 diabetes mellitus. We present two cases of diabetes mellitus associated with clozapine treatment. One case resolved entirely upon withdrawal of the drug, whereas the other did not. We discuss the molecular basis of the diabetogenic action of clozapine and recommendations for monitoring.
authors.affiliation: West London Mental Health NHS Trust, John Conolly Wing, Middlesex, UK.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Tovey
authors.forename: Hagen
authors.initials: H
authors.lastname: Rampes
authors.forename: Callum
authors.initials: C
authors.lastname: Livingstone
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000150:complications / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D003024:Clozapine